Waystar Stock Jumps 8.6% on Reports of Strategic Review and Potential Sale

Key Facts

1Waystar shares climbed 8.60% to $27.05 following reports that the company is evaluating strategic options, including a potential sale.

2A Barclays analyst set a new price target for Waystar at $30.00, suggesting a potential upside of approximately 11.57%.

In a move reflecting heightened M&A activity within the healthcare software sector, Waystar shares climbed 8.60% to reach $27.05. This surge follows reports that the company is evaluating strategic options, including a potential sale that could take the firm private only two years after its initial public offering. According to reports, this strategic review is aimed at maximizing shareholder value amid growing interest in medical technology assets.

From a financial analysis perspective, a Barclays analyst set a new price target for the stock at $30.00, suggesting a potential upside of approximately 11.57%, despite a rating downgrade in the same report. Per market data, the company's market capitalization stands at approximately $5.10 billion, while Barclays (BCS) shares showed relative stability, closing at $25.86 (close September 14, 2026).

Traders should monitor current price levels, as WAY closed at $24.90 (close September 14, 2026) prior to the latest rally. With no immediate sector-specific catalysts in the upcoming economic calendar, M&A news remains the primary driver for the stock. Focus will remain on any official confirmations from Waystar management regarding the progress of the potential sale and its impact on ownership structure.